Fisher Asset Management LLC Boosts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Fisher Asset Management LLC grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 1,609.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 539,025 shares of the company's stock after buying an additional 507,500 shares during the period. Fisher Asset Management LLC owned approximately 0.84% of IDEAYA Biosciences worth $19,179,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Federated Hermes Inc. boosted its stake in shares of IDEAYA Biosciences by 14.8% during the 4th quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company's stock worth $138,185,000 after purchasing an additional 500,046 shares during the period. Walleye Capital LLC bought a new stake in IDEAYA Biosciences during the 3rd quarter valued at about $2,265,000. Boone Capital Management LLC lifted its holdings in IDEAYA Biosciences by 15.0% during the 3rd quarter. Boone Capital Management LLC now owns 570,682 shares of the company's stock valued at $15,397,000 after buying an additional 74,249 shares in the last quarter. Barclays PLC lifted its holdings in IDEAYA Biosciences by 17.8% during the 3rd quarter. Barclays PLC now owns 86,326 shares of the company's stock valued at $2,330,000 after buying an additional 13,049 shares in the last quarter. Finally, Eventide Asset Management LLC bought a new stake in IDEAYA Biosciences during the 3rd quarter valued at about $9,038,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IDYA has been the subject of a number of research analyst reports. Citigroup lifted their price objective on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a "buy" rating in a report on Thursday, March 21st. Royal Bank of Canada boosted their price target on shares of IDEAYA Biosciences from $43.00 to $53.00 and gave the company an "outperform" rating in a report on Wednesday, February 21st. Capital One Financial restated an "overweight" rating on shares of IDEAYA Biosciences in a report on Thursday, February 22nd. JPMorgan Chase & Co. boosted their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the company an "overweight" rating in a report on Friday, February 23rd. Finally, Leerink Partnrs restated an "outperform" rating on shares of IDEAYA Biosciences in a report on Friday, February 23rd. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $46.60.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA traded up $0.91 during mid-day trading on Monday, reaching $43.09. 435,280 shares of the stock were exchanged, compared to its average volume of 836,712. The business's 50 day moving average is $42.68 and its 200-day moving average is $38.26. IDEAYA Biosciences, Inc. has a 1 year low of $18.96 and a 1 year high of $47.74. The company has a market capitalization of $3.22 billion, a P/E ratio of -21.87 and a beta of 0.83.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.05). IDEAYA Biosciences had a negative return on equity of 23.00% and a negative net margin of 483.05%. The firm had revenue of $3.90 million for the quarter, compared to analysts' expectations of $8.84 million. IDEAYA Biosciences's revenue was down 3.0% compared to the same quarter last year. Equities analysts predict that IDEAYA Biosciences, Inc. will post -2.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IDEAYA Biosciences news, insider Briseno Andres Ruiz sold 2,000 shares of the company's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the transaction, the insider now directly owns 24,531 shares in the company, valued at $1,128,916.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 23,557 shares of the company's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the completion of the transaction, the chief executive officer now directly owns 677,887 shares in the company, valued at $30,870,973.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Briseno Andres Ruiz sold 2,000 shares of the company's stock in a transaction on Friday, February 9th. The stock was sold at an average price of $46.02, for a total transaction of $92,040.00. Following the transaction, the insider now owns 24,531 shares of the company's stock, valued at $1,128,916.62. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.